Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 4/20 | 0.58 |
| ▸ | ITGA2B known ✓ | P08514 | 4/20 | 0.58 |
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.57 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.57 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.57 |
| ▸ | TLR2 | O60603 | 2/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.56 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.56 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.56 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.56 |
| ▸ | ECE1 | P42892 | 1/20 | 0.56 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.54 |
| ▸ | CPB1 | P15086 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7284342 | 1.00 | ITGB3 (0.58) | ITGB3ITGA2BSIRT2SIRT1SIRT3 | |
| SCHEMBL9086439 | 0.99 | ITGB3 (0.60) | ITGB3ITGA2BSIRT2SIRT1SIRT3 | |
| SCHEMBL5692870 | 0.99 | ITGB3 (0.60) | ITGB3ITGA2BSIRT2SIRT1SIRT3 | |
| Hydrochloric Acid SCHEMBL8533423 | 0.96 | PRSS1 (0.60) | ITGB3ITGA2BSIRT2SIRT1SIRT3 | |
| SCHEMBL1841203 | 0.95 | PRSS1 (0.61) | ITGB3ITGA2BSIRT2SIRT1SIRT3 | |
| SCHEMBL10723335 | 0.95 | PRSS1 (0.61) | ITGB3ITGA2BSIRT2SIRT1SIRT3 | |
| SCHEMBL1841202 | 0.95 | PRSS1 (0.61) | ITGB3ITGA2BSIRT2SIRT1SIRT3 | |
| Hydrochloric Acid SCHEMBL10586697 | 0.93 | SIRT2 (0.58) | ITGB3ITGA2BSIRT2SIRT1SIRT3 | |
| Hydrochloric Acid SCHEMBL3952159 | 0.92 | SIRT2 (0.60) | ITGB3ITGA2BSIRT2SIRT1SIRT3 | |
| Hydrochloric Acid SCHEMBL3952162 | 0.92 | SIRT2 (0.60) | ITGB3ITGA2BSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250031699-A1 | Method for Controlling Parasitic Plants | AJINOMOTO CO., INC. (JP) | 2025-01-30 | — | — | US | disclosed |
| EP-0522004-B1 | USE OF COPPER(II) CONTAINING COMPOUNDS TO ACCELERATE WOUND HEALING | PROCYTE CORP (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5430018-A | Cyclohexapeptide with basic nitrogen containing alkylamide groups | MERCK & CO., INC. (US) | 1995-07-04 | — | — | US | disclosed |
| EP-0420914-B1 | COSMETIC AND SKIN TREATMENT COMPOSITIONS | PROCYTE CORP (US) | 1994-03-09 | — | — | EP | disclosed |
| EP-0538027-A2 | Cyclohexapeptides | MERCK & CO. INC. (US) | 1993-04-21 | — | — | EP | disclosed |
| EP-0522004-A1 | USE OF COPPER(II) CONTAINING COMPOUNDS TO ACCELERATE WOUND HEALING | PROCYTE CORPORATION (US) | 1993-01-13 | — | — | EP | disclosed |
| EP-0514460-A1 | ANTI-OXIDATIVE AND ANTI-INFLAMMATORY METAL:PEPTIDE COMPLEXES AND USES THEREOF | PROCYTE CORPORATION (US) | 1992-11-25 | — | — | EP | disclosed |
| WO-1991014437-A2 | USE OF COPPER(II) CONTAINING COMPOUNDS TO ACCELERATE WOUND HEALING | PROCYTE CORPORATION (US) | 1991-10-03 | — | — | WO | disclosed |
| WO-1991012267-A1 | ANTI-OXIDATIVE AND ANTI-INFLAMMATORY METAL:PEPTIDE COMPLEXES AND USES THEREOF | PROCYTE CORPORATION (US) | 1991-08-22 | — | — | WO | disclosed |
| EP-0420914-A1 | COSMETIC AND SKIN TREATMENT COMPOSITIONS. | PROCYTE CORP (US) | 1991-04-10 | — | — | EP | disclosed |
| WO-1989012441-A1 | COSMETIC AND SKIN TREATMENT COMPOSITIONS | PROCYTE CORPORATION (US) | 1989-12-28 | — | — | WO | disclosed |
| EP-0192609-A2 | Acylated hexose derivatives and method for their preparation | CIBA-GEIGY AG (CH) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250031699-A1 | Method for Controlling Parasitic Plants | PTMS, DAO, GNMT | ITGB3 3792/4885ITGA2B 4596/4885DPP4 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.